Product Center
Ab&B Bio Tech CO., LTD. JS has been awarded multiple BioCon Awards for 2022!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-09-09
- Views:
(Summary description)Recently, the 9th International BioCon Expo 2022 was grandly held at the Hangzhou International Expo Center. At this conference, Ab&B Bio Tech CO., LTD. JS and its founder Mr. An Youcai were respectiv
Ab&B Bio Tech CO., LTD. JS has been awarded multiple BioCon Awards for 2022!
(Summary description)Recently, the 9th International BioCon Expo 2022 was grandly held at the Hangzhou International Expo Center. At this conference, Ab&B Bio Tech CO., LTD. JS and its founder Mr. An Youcai were respectiv
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-09-09 16:18
- Views:
Recently, the 9th International BioCon Expo 2022 was grandly held at the Hangzhou International Expo Center. At this conference, Ab&B Bio Tech CO., LTD. JS and its founder Mr. An Youcai were respectively awarded the honorary titles of "Most Valuable Biotechnology Enterprise of the Year" and "Outstanding Founder of the Biotechnology Industry of the Year". The double honor fully reflects the high recognition of Ab&B Bio Tech CO., LTD. JS's achievements in the field of innovative vaccines in the industry!
Mr. An Youcai, Chairman/General Manager of Ab&B Bio Tech CO., LTD. JS, said: It's a great surprise to receive such an award! Thank you to all the experts, judges, and industry insiders for recognizing Ab&B Bio Tech CO., LTD. JS. Ab&B Bio Tech CO., LTD. JS will use this as an incentive to strive to maintain resonance with the national "14th Five Year Plan" and the national goal of "expanding and strengthening the bioeconomy". We will always face the unmet clinical needs of the world, remember the mission of making global technological innovation vaccines, let China use global innovation vaccines, and let the world use high-quality Chinese vaccines!
Professor Chen Ze, Vice General Manager/Chief Scientist of Ab&B Bio Tech CO., LTD. JS, gave a keynote speech: Professor Chen gave a detailed explanation of the development and application of influenza vaccines, and unveiled the mysterious veil of the company's first class new drug product, the quadrivalent influenza virus subunit vaccine. He scientifically and detailedly analyzed the product advantages, which made everyone look forward to the product's launch!
The road is long and winding, I will search up and down! The company will continue to increase investment in research and development, and strive to develop innovative vaccines. Strive to become the "star power" of biopharmaceuticals, and work together towards the future!
Relevant information
-
Ab&B Bio and Yither Bio have both obtained qualification certification!Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) have been recognized as Jiangsu Province's specialized and innovative small and medium-sized enterprises and national high-tech enterprises, respectively. - The kickoff meeting for clinical research on the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome was successfully held 12-25
- Influenza virus subunit vaccine (adjuvant) IND application approved 10-30
- The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
